--- title: "Rein Therapeutics FY2025 operating loss narrows 22.2% to $(50.6) million; net loss narrows 20.7% to $(50) million" type: "News" locale: "en" url: "https://longbridge.com/en/news/280685466.md" description: "Rein Therapeutics reported a narrowed FY2025 operating loss of $50.6 million, down 22.2% from the previous year, with a net loss of $49.9 million compared to $62.9 million. Total operating expenses decreased to $50.6 million, including R&D expenses of $11.0 million and G&A expenses of $10.9 million. The impairment loss on intangible assets was $28.7 million. The company has $3.2 million in cash and expects to fund operations into Q2 2026 with additional proceeds from promissory notes." datetime: "2026-03-26T20:37:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280685466.md) - [en](https://longbridge.com/en/news/280685466.md) - [zh-HK](https://longbridge.com/zh-HK/news/280685466.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/280685466.md) | [繁體中文](https://longbridge.com/zh-HK/news/280685466.md) # Rein Therapeutics FY2025 operating loss narrows 22.2% to $(50.6) million; net loss narrows 20.7% to $(50) million - Rein published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025. \* Net loss was USD 49.9 million, compared with a USD 62.9 million net loss a year earlier. \* Total operating expenses were USD 50.6 million, down 22.24%, including R&D expense of USD 11.0 million (down 22.59%) and G&A expense of USD 10.9 million (down 21.36%). \* Impairment loss on intangible assets was USD 28.7 million, down 22.43%, after the company paused development activities related to LTI-01 for an indefinite period. \* Cash and cash equivalents were USD 3.2 million, and management said this, together with USD 4.3 million of proceeds received under promissory notes issued in January and February 2026, is expected to fund operations into the second quarter of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rein Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-126385), on March 26, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here ### Related Stocks - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Rein Therapeutics Inc. (RNTX.US)](https://longbridge.com/en/quote/RNTX.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals](https://longbridge.com/en/news/280011451.md) - [Indaptus Therapeutics Announces Major Leadership and Board Changes](https://longbridge.com/en/news/280372192.md) - [Soligenix publishes corporate presentation; pipeline targets rare diseases with ~$2 billion in potential global annual sales](https://longbridge.com/en/news/280680800.md) - [FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease](https://longbridge.com/en/news/280632064.md) - [Stocks in Play: Sernova Biotherapeutics](https://longbridge.com/en/news/280329687.md)